Cargando…

AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis

Chromosomal translocations are one of the hallmarks of acute myeloid leukemia (AML), often leading to gene fusions and expression of an oncofusion protein. Over recent years it has become clear that most of the AML associated oncofusion proteins molecularly adopt distinct mechanisms for inducing leu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Abhishek A., Mandoli, Amit, Prange, Koen H.M., Laakso, Marko, Martens, Joost H.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355061/ https://www.ncbi.nlm.nih.gov/pubmed/28030795 http://dx.doi.org/10.18632/oncotarget.14150

Ejemplares similares

Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knockin mice
por: Hyde, R. Katherine, et al.
Publicado: (2015)

FACSorting help to analyze a rare case of acute myeloid leukemia with concurrent AML1‐ETO and PML‐RARA
por: Chen, Man, et al.
Publicado: (2021)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML
por: Liu, Peng, et al.
Publicado: (2021)

Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1
por: Lukes, Julius, et al.
Publicado: (2020)

TAF1 plays a critical role in AML1-ETO driven leukemogenesis
por: Xu, Ye, et al.
Publicado: (2019)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
por: Loke, Justin, et al.
Publicado: (2017)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
por: Mu, Guangfu, et al.
Publicado: (2020)

Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice
por: Saida, Satoshi, et al.
Publicado: (2019)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions
por: Qin, Wei, et al.
Publicado: (2022)

Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice
por: Wartman, Lukas D., et al.
Publicado: (2012)

The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling
por: Stoner, Samuel A., et al.
Publicado: (2020)

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
por: Meier, Ruth, et al.
Publicado: (2022)

MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia
por: Prange, K H M, et al.
Publicado: (2017)

Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding
por: Ptasinska, A, et al.
Publicado: (2012)

TTMV-RARA fusion as a recurrent cause of AML with APL characteristics
por: Sala-Torra, Olga, et al.
Publicado: (2022)

Analytical study of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1(p210), and KMT2-MLLT3 in Mexican children with acute myeloid leukemia: A multicenter study of the Mexican interinstitutional group for the identification of the causes of childhood leukemia (MIGICCL)
por: Sepúlveda-Robles, Omar, et al.
Publicado: (2022)

RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction
por: Ptasinska, Anetta, et al.
Publicado: (2019)

RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction
por: Ptasinska, Anetta, et al.
Publicado: (2019)

Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells
por: Trombly, Daniel J, et al.
Publicado: (2015)

Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia
por: Cho, Eun Kyung, et al.
Publicado: (2003)

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients
por: Yang, Min, et al.
Publicado: (2022)

AML1-ETO-Related Fusion Circular RNAs Contribute to the Proliferation of Leukemia Cells
por: Wang, Ying, et al.
Publicado: (2022)

PML-RARα与AML1-ETO融合基因共表达急性髓系白血病一例报告并附文献复习
Publicado: (2018)

Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion
por: Kuhlman, Justin J., et al.
Publicado: (2021)

MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
por: Johnson, Daniel T., et al.
Publicado: (2021)

A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML
por: Heimbruch, Katelyn E., et al.
Publicado: (2021)

A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis
por: Sun, Xiao-Jian, et al.
Publicado: (2013)

AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
por: Rejeski, Kai, et al.
Publicado: (2021)

A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells
por: Gao, Xiao-ning, et al.
Publicado: (2013)

Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study
por: Xu, Dan, et al.
Publicado: (2023)

Educational Case: Acute Promyelocytic Leukemia With PML-RARA
por: Kunak, Rebecca L., et al.
Publicado: (2019)

The oncofusion protein FUS–ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia
por: Sotoca, A M, et al.
Publicado: (2016)

The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
por: Jaffray, Ellis G., et al.
Publicado: (2023)

Targeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models
por: Wu, Qing, et al.
Publicado: (2016)

Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency
por: Perez, Monika W., et al.
Publicado: (2021)

Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia
por: Dou, Liping, et al.
Publicado: (2019)

The DNA Binding Property of PML/RARA but Not the Integrity of PML Nuclear Bodies Is Indispensable for Leukemic Transformation
por: Liu, Xi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1apubq85p8e0698nte09pedhi1